Androgenetic alopecia (AGA) research presents a unique set of challenges for clinical trials. From the nuances of standardizing photographic endpoints to managing the high expectations of a motivated but discerning patient population, trials in this therapeutic area demand both clinical sensitivity and operational precision. DelRicht Research has built a reputation for meeting these challenges head-on, delivering the consistent results and high-quality data necessary to advance AGA therapeutics.

Proven Experience and Impact

Over the past five years, DelRicht Research has successfully conducted 6 androgenetic alopecia trials, enrolling 530+ participants across our network. Our performance is defined by more than just numbers; it is defined by leadership. With 7 sites achieving Top Enroller status in AGA studies over the last five years, our network consistently demonstrates the ability to outpace industry benchmarks while maintaining data integrity.

In an indication where “first patient in” is a critical metric for momentum, DelRicht has repeatedly delivered, including more than three first patient screened or enrolled milestones across our recent studies. This track record underscores the importance of a site network that can mobilize quickly and maintain recruitment momentum throughout the study lifecycle.

Nationwide Network and Infrastructure

DelRicht’s dermatology research network is powered by 8 experienced sites nationwide, supported by 9 specialized dermatology investigators with over 187 years of collective principal investigator experience. Our physician-led model is deeply embedded within high-volume, community-based clinics. This allows for immediate access to real-world patient populations—including those in underserved areas—ensuring our recruitment reflects the diverse demographics of those affected by hair loss.

Each site is equipped with a full-service infrastructure, featuring secure investigational product (IP) storage, access to local laboratories and specialty care providers, and standardized workflows designed for inspection readiness.

Operational Expertise for Complex Protocols

Androgenetic alopecia protocols often require heightened technical proficiency, particularly regarding topical applications and specialized imaging. DelRicht’s sites are structured to address these nuances directly. Our teams are expertly trained to:

• Access Priority Cohorts: Managing the distinct recruitment needs for both male and female pattern hair loss, including moderate-to-severe, biologic naive, and inadequate responders.
• Optimize Adherence and Patient Support: Ensuring participants follow strict topical or oral dosing regimens to safeguard endpoint integrity.
• Monitor Safety and Efficacy: Utilizing experienced PIs to oversee the long-term safety profiles essential for dermatological FDA submissions.

With an average 96% success rate in meeting or exceeding trial enrollment goals, our operational model is built to mitigate the risks that typically stall dermatology programs.

Patient-Centered Retention and Compliance

In hair loss research, long-term adherence is vital for observing meaningful changes in hair density and growth cycles. Retention can be challenging when results are gradual, but DelRicht mitigates this risk through integrated patient support systems. Our dedicated, full-time site staff provide comprehensive participant education, real-time consent support, and proactive adherence follow-up.

By building trust and providing continuous education on the science of AGA, we ensure that participants remain engaged from baseline to the final follow-up, reducing data variability and strengthening the overall trial power.

A Trusted Partner Across Therapeutic Areas

While androgenetic alopecia is a core area of excellence, DelRicht Research brings broad therapeutic experience across the dermatology field. Our investigators have successfully completed trials in atopic dermatitis, vitiligo, psoriasis, acne, hidradenitis suppurativa (HS), eczema, and verruca vulgaris. This cross-indication knowledge allows our team to navigate complex trial designs and adapt our operational models to meet the specific needs of any dermatology sponsor.

Moving Medicine Forward

From achieving top-enroller status to maintaining industry-leading retention rates, DelRicht Research has demonstrated the ability to deliver in the competitive landscape of dermatology. For sponsors and CROs seeking a proven partner with direct access to high-value cohorts—including inadequate responders and early-onset progressors—our physician-led network offers the speed, infrastructure, and expertise needed to ensure trial success.